Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor

Details

Serval ID
serval:BIB_F81871332CB5
Type
Article: article from journal or magazin.
Collection
Publications
Title
Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor
Journal
British Journal of Cancer
Author(s)
Leyvraz  S., Ketterer  N., Perey  L., Bauer  J., Vuichard  P., Grob  J. P., Schneider  P., von Fliedner  V., Lejeune  F., Bachmann  F.
ISSN
0007-0920 (Print)
Publication state
Published
Issued date
07/1995
Volume
72
Number
1
Pages
178-82
Notes
Journal Article --- Old month value: Jul
Abstract
Dose intensity may be an important determinant of the outcome in cancer chemotherapy, but is often limited by cumulative haematological toxicity. The availability of haematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and of peripheral blood progenitor cell (PBPC) transplantation has allowed the development of a new treatment strategy in which several courses of high-dose combination chemotherapy are administered for the treatment of solid tumours. PBPCs were mobilised before chemotherapy using 12 or 30 micrograms kg-1 day-1 G-CSF (Filgrastim) for 10 days, and were collected by 2-5 leucaphereses. The yields of mononuclear cells, colony-forming units and CD34-positive cells were similar at the two dose levels of Filgrastim, and the numbers of PBPCs were sufficient for rescue following multiple cycles of chemotherapy. High-dose chemotherapy (cyclophosphamide 2.5 g m-2 for 2 days, etoposide 300 mg m-2 for 3 days and cisplatin 50 mg m-2 for 3 days) was administered sequentially for a median of three cycles (range 1-4) to ten patients. Following the 30 evaluable cycles, the median duration of leucopenia < or = 0.5 x 10(9) l-1 and < or = 1.0 x 10(9) l-1 was 7 and 8 days respectively. The median time of thrombopenia < or = 20 x 10(9) l-1 was 6 days. There was no cumulative haematological toxicity. The duration of leucopenia, but not of thrombopenia, was inversely related to the number of reinfused CFU-GM (granulocyte-macrophage colony-forming units). In the majority of patients, neurotoxicity and ototoxicity became dose limiting after three cycles of therapy. However, the average dose intensity delivered was about three times higher than in a standard regimen. The complete response rate in patients with small-cell lung cancers was 66% (95% CI 30-92%) and the median progression-free survival and overall survival were 13 months and 17 months respectively. These results are encouraging and should be compared, in a randomised fashion, with standard dose chemotherapy.
Keywords
Adult Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Cell Separation Dose-Response Relationship, Drug Female Granulocyte Colony-Stimulating Factor/*therapeutic use *Hematopoietic Stem Cell Transplantation Humans Male Middle Aged Neoplasms/*drug therapy
Pubmed
Web of science
Create date
28/01/2008 9:32
Last modification date
03/03/2018 22:51
Usage data